Large Molecule Patents
Avastin is a drug owned by Genentech, Inc.. It is protect by 12 US patents. Given below is the list of those patents along with their expiration dates.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10208355 | GENENTECH, INC. | Method of treatment for glioblastoma by administering a VEGF antagonist |
Jul, 2035
(10 years from now) | Active |
| US10274466 | GENENTECH, INC. | Elucidation of ion exchange chromatography input optimization |
Jul, 2035
(10 years from now) | Active |
| US9441035 | GENENTECH, INC. | Cell culture media and methods of antibody production |
Apr, 2034
(9 years from now) | Active |
| US10906934 | GENENTECH, INC. | Protein purification methods |
Oct, 2033
(8 years from now) | Active |
| US10513697 | GENENTECH, INC. | CO2 profile cultivation |
Sep, 2032
(7 years from now) | Active |
| US9487809 | GENENTECH, INC. | Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
Jan, 2032
(7 years from now) | Active |
| US10704071 | GENENTECH, INC. | Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
Aug, 2031
(6 years from now) | Active |
| US10011856 | GENENTECH, INC. | Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
May, 2031
(6 years from now) | Active |
| US8460895 | GENENTECH, INC. | Method for producing recombinant proteins with a constant content of pCO2 in the medium |
Aug, 2029
(4 years from now) | Active |
| US10906986 | GENENTECH, INC. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Jul, 2028
(3 years from now) | Active |
| US7485704 | GENENTECH, INC. | Reducing protein A leaching during protein A affinity chromatography |
Mar, 2025
(3 months from now) | Active |
| US9795672 | GENENTECH, INC. | Treatment with anti-VEGF antibodies |
May, 2024
(5 months ago) |
Expired |
Avastin's Family Patents
Explore Our Curated Drug Screens
About Avastin
Active Ingredients:
Approval Date:
Dosage:
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG/4ML (25MG/ML) | Injection | Rx | Intravenous |
| 100MG/4ML (25MG/ML) | Injection | Rx | Intravenous |
| 400MG/16ML (25MG/ML) | Injection | Rx | Intravenous |
| 400MG/16ML (25MG/ML) | Injection | Rx | Intravenous |
| 400MG/16ML (25MG/ML) | Injection | Rx | Intravenous |
| 100MG/4ML (25MG/ML) | Injection | Rx | Intravenous |